Morepen Laboratories files FY26 BRSR report, details sustainability metrics

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Morepen Laboratories filed its FY26 BRSR report, disclosing a turnover of ₹16,766.7 crore
  • Capital expenditure on environmental technologies rose to 9.39% from 0% in FY25
  • Energy intensity improved to 272.43 GJ per crore INR of turnover
  • Scope 1 emissions decreased to 4,977.55 metric tonnes CO2 equivalent
  • Workforce includes 1,314 permanent employees and 1,755 workers
powered bylight_fuzz_icon
49885635

*this image is generated using AI for illustrative purposes only.

Morepen Laboratories has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing outlines the company’s environmental, social, and governance performance across its pharmaceutical and medical device operations.

The company reported a turnover of ₹16,766.7 crore and a net worth of ₹12,454.1 crore for FY26. Exports contributed 40% of total turnover, with the business serving over 80 countries. The API segment accounted for 56.33% of turnover, while medical devices contributed 35.60%.

Environmental Performance

Morepen allocated 9.39% of its capital expenditure to technologies improving environmental and social impacts in FY26, up from 0% in FY25. Key initiatives included transitioning boiler fuel to biomass at its Baddi facility and converting boilers to dual-fuel LPG systems at Parwanoo.

Total energy consumption rose to 456,771.57 GJ from 437,741.34 GJ in the prior year. However, energy intensity improved to 272.43 GJ per crore INR of turnover, down from 282.97 GJ. Scope 1 greenhouse gas emissions fell to 4,977.55 metric tonnes from 5,941.30 metric tonnes, while Scope 2 emissions increased to 22,950.33 metric tonnes.

Social Metrics

The workforce comprised 1,314 permanent employees and 1,755 workers as of March 31, 2026. Women constituted 9.59% of permanent employees and 12.76% of workers. The company reported zero fatalities and zero lost-time injuries among employees, with a Lost Time Injury Frequency Rate (LTIFR) of 0.24 for workers.

What the Numbers Show

Capital expenditure directed toward environmental improvements surged to 9.39% of total capex in FY26, marking a significant shift from zero such spending in FY25. This investment coincided with a reduction in energy intensity per rupee of turnover, suggesting that recent green technology upgrades are enhancing operational efficiency despite higher absolute energy consumption.

Historical Stock Returns for Morepen Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+6.91%+18.01%+94.27%+153.74%+131.05%+116.00%

How will the significant increase in environmental capex impact Morepen's short-term profit margins versus long-term operational cost savings?

What specific regulatory or market pressures in key export destinations are driving the 40% export contribution, and how vulnerable is this segment to trade policy shifts?

Given the rise in Scope 2 emissions despite improved energy intensity, what strategies is Morepen employing to decarbonize its electricity supply?

Morepen Laboratories declares ₹0.20 per share final dividend for FY26

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Morepen Laboratories declared a final dividend of ₹0.20 per equity share for FY26
  • The 41st AGM is scheduled for September 26, 2026 via VC/OAVM
  • Record date for dividend eligibility is set for September 19, 2026
  • Physical shareholders must update KYC by August 28, 2026 for electronic payment
powered bylight_fuzz_icon
49268363

*this image is generated using AI for illustrative purposes only.

Morepen Laboratories declared a final dividend of ₹0.20 per equity share for the financial year ended March 31, 2026. The Board of Directors approved the payout during its meeting on May 26, 2026. Shareholders on record as of September 19, 2026 will be eligible for the distribution.

The company scheduled its 41st Annual General Meeting (AGM) for Saturday, September 26, 2026 at 1:00 pm. The meeting will be held through Video Conferencing or Other Audio Visual Means (VC/OAVM) in compliance with Ministry of Corporate Affairs and SEBI regulations.

Dividend Details

The final dividend is subject to deduction of tax at source (TDS) as applicable under the Income Tax Act. Payment will be made within 30 days of approval by shareholders at the AGM. The company emphasized that dividends are taxable in the hands of shareholders.

Detail Information
Final Dividend ₹0.20 per equity share
Record Date September 19, 2026
AGM Date September 26, 2026
Financial Year FY26

Shareholder Instructions

Shareholders holding shares in physical form must ensure their KYC details are updated to receive dividends electronically. SEBI mandates electronic payment for all security holders, regardless of whether shares are held in demat or physical form. Physical shareholders should submit Form ISR-1 to the Registrar and Transfer Agent (RTA), MS Services Limited, by August 28, 2026.

Demat holders must verify that their bank account details are correctly updated with their Depository Participant (DP). Failure to update KYC may delay dividend credit. The company will send specific instructions via email to registered addresses.

Special Window for Physical Shares

A special window for transfer and dematerialization of physical shares purchased before April 1, 2019 remains open until February 4, 2027. Eligible shareholders can submit original share certificates and transfer deeds. Shares processed under this window will be credited in demat form and subject to a one-year lock-in period from the date of registration.

Historical Stock Returns for Morepen Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+6.91%+18.01%+94.27%+153.74%+131.05%+116.00%

How does the ₹0.20 dividend payout ratio compare to Morepen Laboratories' historical averages and peer group in the pharmaceutical sector?

What impact might the one-year lock-in period for dematerialized physical shares have on short-term stock liquidity and trading volume?

Will Morepen Laboratories adjust its capital allocation strategy for FY27 given the current dividend payout and ongoing regulatory compliance costs?

More News on Morepen Laboratories

1 Year Returns:+131.05%